Literature DB >> 1584349

Carbon dioxide reactivity in the evaluation of cerebral ischemia.

J D Miller1, R R Smith, H R Holaday.   

Abstract

Carbon dioxide reactivity, as measured by transcranial Doppler, has been determined in a group of patients with carotid artery disease and compared to a control group. CO2 reactivity was readily evaluated using transcranial Doppler by having the patients breathe 5% CO2 via a rebreathing circuit. There were significant differences (P less than 0.01) between the symptomatic patients and asymptomatic controls, as well as between symptomatic and asymptomatic hemispheres (P less than 0.05) in the patients with carotid artery disease. Five patients had revascularization procedures with all showing improved CO2 reactivity in the symptomatic and asymptomatic hemispheres. The improvement occurred early in patients after carotid endarterectomy. Two patients demonstrated improved reactivity at 6 to 13 months after extracranial-to-intracranial bypass. Transcranial Doppler has proven to be an easily performed and repeatable method of evaluating CO2 reactivity and its response to treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1584349     DOI: 10.1227/00006123-199204000-00008

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

Review 1.  Cerebral vascular dysregulation in the ischemic brain.

Authors:  Alexander Kunz; Costantino Iadecola
Journal:  Handb Clin Neurol       Date:  2009

2.  Cerebral haemodynamic considerations in obstructive carotid artery disease.

Authors:  A Sorteberg; W Sorteberg; K F Lindegaard; H Nornes
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Middle cerebral artery flow velocity decreases and electroencephalogram (EEG) changes occur as acute hypercapnia reverses.

Authors:  Pinchas Halpern; Miri Y Neufeld; Kobi Sade; Aviel Silbiger; Oded Szold; Natan M Bornstein; Patrick Sorkine
Journal:  Intensive Care Med       Date:  2003-08-02       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.